English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

A dissolution test for darifenacin 15-mg extended-release tablets was developed and validated according to current FDA and USP guidelines. The sink condition was evaluated, and a 24–1 factorial design was employed for method development. In vivo data were obtained from the literature, and the fraction and percentage of dose absorbed (FA) was calculated using the Wagner–Nelson method. The best dissolution conditions were achieved using USP Apparatus 1 (basket) with 900 mL of dissolution medium containing 2% SDS at 50 rpm. A successful linear regression model of fraction of drug absorbed versus dissolved was achieved (R2 = 0.9997, p < 0.05). The best fit for drug release kinetics was provided by the Korsmeyer–Peppas model. The validation was performed with an HPLC–UV method, and results for specificity, linearity, precision, and accuracy were in accordance with guidelines. The proposed method achieved a Level A correlation with the fraction of dose absorbed. Additionally, the discriminatory power of the method was challenged. The results show that the proposed test is adequate to evaluate the in vitro profile for extended-release darifenacin tablets.

Development and Validation of a Discriminating Dissolution Method for Darifenacin Extended-Release Tablets